Peter Turcsanyi

6PUBLICATIONS
22CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursHaematologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 12, 2026
Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group.

|Mar 27, 2023
Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).

Martin Špaček, Lukáš Smolej, Martin Šimkovič

|Aug 27, 2022
Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers.

Anna Petrackova, Jakub Savara, Peter Turcsanyi

|Oct 13, 2021
Towards a Better Characterisation of Leukemic Cells in Chronic Lymphocytic Leukaemia: Cell-Size Heterogeneity Reflects Their Activation Status and Migratory Abilities.

Gayane Manukyan, Zuzana Mikulkova, Peter Turcsanyi

|Dec 06, 2020
External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score.

Lukáš Smolej, Peter Turcsányi, Zuzana Kubová

|Aug 18, 2020
High CXCR3 on Leukemic Cells Distinguishes IgHV mut from IgHV unmut in Chronic Lymphocytic Leukemia: Evidence from CD5high and CD5low Clones.

Gayane Manukyan, Tomas Papajik, Zuzana Mikulkova

Pageof 1

Frequent Collaborators

3 joint publications

Jakub Savara

3 joint publications

Eva Kriegova

2 joint publications

Lukáš Smolej

2 joint publications

Martin Špaček